COEP logo

Coeptis Therapeutics (COEP) Company Overview

Profile

Full Name:

Coeptis Therapeutics Holdings, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

December 17, 2020

Indexes:

Not included

Description:

Coeptis Therapeutics (COEP) is a biotechnology company focused on developing innovative cell therapies for cancer treatment. They aim to improve patient outcomes by harnessing the power of the immune system to target and destroy cancer cells more effectively.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Nov 9, 2023

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Dec 31, 2024

Analyst ratings

Recent major analysts updates

Sep 22, 23 Ladenburg Thalmann
Buy
May 18, 23 EF Hutton
Buy
May 10, 23 EF Hutton
Buy
Apr 19, 23 JonesTrading
Buy
Apr 5, 23 EF Hutton
Buy
Mar 29, 23 EF Hutton
Buy
Dec 13, 22 EF Hutton
Buy
Dec 12, 22 EF Hutton
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration
COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration
COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration
COEP
prnewswire.comFebruary 6, 2025

WEXFORD, Pa. , Feb. 6, 2025 /PRNewswire/ -- COEPTIS, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a pioneering technology company dedicated to advancing cutting-edge technologies and artificial intelligence at the forefront of innovative biotechnology therapeutic solutions, today announced the successful closure of an additional $5.7 million in its final Series A Preferred Offering, bringing the total financing round to $10 million.

Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation
Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation
Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation
COEP
prnewswire.comJanuary 30, 2025

Rebranding Signals Strategic Shift Beyond Biopharmaceuticals, Highlights Commitment to Technology, Artificial Intelligence and Shareholder Value WEXFORD, Pa. , Jan. 30, 2025 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, is excited to announce its rebranding to COEPTIS, marking a transformative shift in its business strategy.

Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation
Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation
Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation
COEP
prnewswire.comJanuary 23, 2025

Coeptis Harnesses AI Advances and Blockchain Initiatives to Drive Operational Efficiency and Strategic Growth WEXFORD, Pa. , Jan. 23, 2025 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, is excited to announce the expansion of its technological initiatives to include cutting-edge artificial intelligence and innovative blockchain solutions.

Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform
Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform
Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform
COEP
prnewswire.comJanuary 7, 2025

Coeptis Secures Five New Clients With Total Contract Value of $1.7 Million Dollars With More On The Horizon Signaling AI-Driven Marketing Innovations in Biopharma for Coeptis WEXFORD, Pa. , Jan. 7, 2025 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, is excited to announce the initial rollout of its recently introduced NexGenAI Affiliates Network platform.

Coeptis Therapeutics Announces Reverse Stock Split
Coeptis Therapeutics Announces Reverse Stock Split
Coeptis Therapeutics Announces Reverse Stock Split
COEP
prnewswire.comDecember 27, 2024

WEXFORD, Pa. , Dec. 27, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced it will proceed with a 1-for-20 reverse stock split (the "Reverse Split") of its issued and outstanding shares of common stock, par value $0.0001, following authorization by its board of directors (the "Board") and majority stockholders to effect a reverse stock split by a ratio of not less than 1-for-3 and not more than 1-for-40 (the "Reverse Split Range"), with the Board having the discretion as to whether or not the Reverse Split is to be effected, and the exact ratio to be set at a whole number within the Reverse Split Range.

Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies
Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies
Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies
COEP
prnewswire.comDecember 26, 2024

Coeptis Aims to Bring AI Innovation in Biotechnology and Technology WEXFORD, Pa. , Dec. 26, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company specializing in innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, proudly announces the completion of its acquisition of the NexGenAI Affiliates Network platform alongside the official launch of Coeptis Technologies.

Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies
Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies
Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies
COEP
prnewswire.comDecember 12, 2024

Coeptis Technologies Signs Binding Letter of Intent to Acquire Key Assets from a Risk Mitigation Software Company with 10,000 customers in over 100 countries , Expanding into the Booming Data Security Sector following the upcoming acquisition of NexGenAI Affiliates Network WEXFORD, Pa. , Dec. 12, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, is excited to announce the official launch of Coeptis Technologies, a new division aimed at diversifying and enhancing the company's growth potential.

Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries
Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries
Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries
COEP
prnewswire.comDecember 3, 2024

The Acquisition of NexGenAI Affiliates Network Expands Company's Capabilities and Drives Innovation, Operational Efficiency, and Opportunity for Growth WEXFORD, Pa. , Dec. 3, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, is pleased to announce the execution of a Binding Letter of Intent for the acquisition of NexGenAI Affiliates Network, a platform developed by NexGenAI Solutions Group and its affiliates ("NexGenAI") that offers AI-powered marketing software and robotic process automation ("RPA") capabilities.

Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development
Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development
Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development
COEP
prnewswire.comNovember 7, 2024

Study results demonstrate the safety and feasibility of adoptive immunotherapy using allogeneic off-the-shelf NK cells in hospitalized patients with COVID at high risk for progression of disease DVX201, the first allogeneic NK cell therapy derived from pooled donor cord blood CD34+ cells, was administered to 9 patients with no dose limiting toxicities, cytokine release syndrome or infusion toxicities WEXFORD, Pa. , Nov. 7, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced that results from their Phase 1 study evaluating DVX201, an allogeneic natural killer (NK) cell therapy, for the treatment of patients hospitalized with COVID-19 has been accepted for publication in Molecular Therapy Methods and Clinical Development.

Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use
Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use
Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use
COEP
prnewswire.comOctober 24, 2024

WEXFORD, Pa. , Oct. 24, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced the expansion of its license agreement with Deverra Therapeutics Inc. ("Deverra"), broadening the potential applications of its allogeneic natural killer (NK) cell technology.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the ticker symbol for Coeptis Therapeutics?
  • Does Coeptis Therapeutics pay dividends?
  • What sector is Coeptis Therapeutics in?
  • What industry is Coeptis Therapeutics in?
  • What country is Coeptis Therapeutics based in?
  • When did Coeptis Therapeutics go public?
  • Is Coeptis Therapeutics in the S&P 500?
  • Is Coeptis Therapeutics in the NASDAQ 100?
  • Is Coeptis Therapeutics in the Dow Jones?
  • When was Coeptis Therapeutics's last earnings report?
  • When does Coeptis Therapeutics report earnings?
  • Should I buy Coeptis Therapeutics stock now?

What is the ticker symbol for Coeptis Therapeutics?

The ticker symbol for Coeptis Therapeutics is NASDAQ:COEP

Does Coeptis Therapeutics pay dividends?

No, Coeptis Therapeutics does not pay dividends

What sector is Coeptis Therapeutics in?

Coeptis Therapeutics is in the Healthcare sector

What industry is Coeptis Therapeutics in?

Coeptis Therapeutics is in the Biotechnology industry

What country is Coeptis Therapeutics based in?

Coeptis Therapeutics is headquartered in United States

When did Coeptis Therapeutics go public?

Coeptis Therapeutics's initial public offering (IPO) was on December 17, 2020

Is Coeptis Therapeutics in the S&P 500?

No, Coeptis Therapeutics is not included in the S&P 500 index

Is Coeptis Therapeutics in the NASDAQ 100?

No, Coeptis Therapeutics is not included in the NASDAQ 100 index

Is Coeptis Therapeutics in the Dow Jones?

No, Coeptis Therapeutics is not included in the Dow Jones index

When was Coeptis Therapeutics's last earnings report?

Coeptis Therapeutics's most recent earnings report was on Nov 9, 2023

When does Coeptis Therapeutics report earnings?

The date for Coeptis Therapeutics's next earnings report has not been announced yet

Should I buy Coeptis Therapeutics stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions